Could oral vaccines shake up the flu shot market? Vaxart's Ph I says maybe

An article form FierceVaccines
October 23, 2014
Flu shots are a driving sales force for more than a couple of vaccine players. But could an oral alternative disrupt the flu vaccine market down the line?
 
New data from Vaxart suggest it's possible. In a Phase I study, its H1N1 tablet vaccine generated protective immunity that measured up to on-the-market options, as measured by hemagglutinin inhibition assay.
 
As John Treanor, infectious disease chief at the University of Rochester Medical Center, said in a statement, there are some significant advantages to providing flu vaccines orally. For instance, tablet vaccines could be brought directly to users at work or school. They'd also avoid needle-phobia and have the potential for faster manufacturing and distribution, a factor that could come up big in the event of a pandemic or outbreak.
 
Read more here.
Common Disease Taxonomy: 
Common Vaccine Taxonomy: 
0